Cargando...

Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder

ABSTRACT: The terminal complement protein (C5) inhibitor eculizumab (Soliris(®)) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) ser...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Drugs
Autor principal: Frampton, James E.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7183484/
https://ncbi.nlm.nih.gov/pubmed/32266705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01297-w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!